<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159756">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01906294</url>
  </required_header>
  <id_info>
    <org_study_id>5050000</org_study_id>
    <nct_id>NCT01906294</nct_id>
  </id_info>
  <brief_title>IMS® DIAREG Diabetes Registry</brief_title>
  <official_title>Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IMS HEALTH GmbH &amp; Co. OHG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IMS HEALTH GmbH &amp; Co. OHG</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observation plan outlines the approach to build a diabetes registry to collect data on
      daily routine of treatment of Type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The choice to establish such a (general and specific) disease patient registry was based on
      several scientific and practical considerations as described in the AHRQ user's guide:
      registries for evaluating patient outcomes (www.ahrq.gov, 2007). From a public health point
      of view, such a register should monitor naturalistic (i.e., unbiased) use of diabetes
      treatment in the community and should primarily guide and assist medical professionals to
      make optimal choices in combating diabetes. The primary focus of this registry is therefore
      to monitor the medical and lifestyle treatment of diabetes in order to enable comparison of
      different treatment options and to provide data for future discussions of optimal treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>routine treatment data (composite of e.g. diagnostics, kind and dosage of pharmacological diabetes treatment)</measure>
    <time_frame>From date of registration every 3 months until end of study (up to 120 months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The objective of the project is to develop a sustainable Type 2 Diabetes Mellitus (T2DM) registry to collect daily routine treatment data (e.g. diagnostics, kind and dosage of pharmacological diabetes treatment) to provide a better understanding of the disease specific epidemiology, treatment patterns, patient relevant outcomes, patient subgroups, specifically among patients with Type 2 Diabetes Mellitus. Further DDG (&quot;Deutsche Diabetes Gesellschaft&quot;) guideline adherence and economic aspects of diabetes treatment should be evaluated on the basis of this registry data.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12000</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes Mellitus</arm_group_label>
    <description>Patients with antidiabetic treatment for Type 2 Diabetes Mellitus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antidiabetic treatment (ATC A10B)</intervention_name>
    <arm_group_label>Type 2 Diabetes Mellitus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Type 2 Diabetes Mellitus
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed written informed consent

          -  Age of 18 years or older

          -  Diagnosis of Type 2 Diabetes Mellitus (T2DM)

        Exclusion Criteria:

        Only patients who don't fulfill the inclusion criteria will be excluded. There will be no
        further possibility for the treating physician to exclude individual patients.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Martin, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Verbund der Katholischen Kliniken Düsseldorf (VKKD) Westdeutschen Diabetes- und Gesundheitszentrum (WDGZ)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerstin Bode-Greuel, Dr. med.</last_name>
    <phone>+49 69 6604</phone>
    <phone_ext>4637</phone_ext>
    <email>KBode-Greuel@de.imshealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Praxis Dr. med. Birgit Böttger</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60325</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Böttger, Dr. med.</last_name>
      <phone>069 74 86</phone>
      <phone_ext>86</phone_ext>
      <email>b.boettger@telemed.de</email>
    </contact>
    <investigator>
      <last_name>Birgit Böttger, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 30, 2013</lastchanged_date>
  <firstreceived_date>July 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
